Author

T. Bekaii-Saab

h-index 4 View on Semantic Scholar

We have 3 of 86 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Harnessing novel agents to target KRAS-driven pathways in pancreatic cancer.

INTRODUCTION Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy in which activating KRAS mutations, present in more than 90% of tumors, constitute the principal oncogenic driver. Advances in structural biology have enabled the pharmacologic targeting of KRAS, a protein historically regarded as 'undrugg...

Joanna Kreidi, C. Hoyek, C. Eslinger et al. · Expert Opinion on Biological... · 0 citations

Open access Aug 2026

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC, an unmet need after first-line immunotherapy.

Nguyen H. Tran, M. Palmer, Angela Ulrich et al. · The Oncologist · 0 citations

Open access Jun 2026

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

Evaluating and monitoring reasoning fidelity should be a prerequisite for safe deployment of LLMs in oncology decision support, as endpoint accuracy alone may mask clinically meaningful reasoning failures.

Matthew Kenaston, U. Ayub, Mihir Parmar et al. · npj Digital Medicine · 0 citations